
Background: Optimal timing for initiating anticoagulation after acute ischemic stroke remains uncertain, requiring a balance between thromboembolic prevention and minimizing the risk of hemorrhagic transformation. Aims: To compare the safety and efficacy of early versus late anticoagulation initiation after acute ischemic stroke. Methods: Retrospective chart review at a tertiary medical center evaluating early (≤7 days from stroke onset) or late (>7 days from stroke onset) anticoagulation initiation for adults admitted to the Neurological Critical Care Unit between January 1, 2019 and June 1, 2024 with an indication for anticoagulation and a diagnosis of moderate-severe or severe acute ischemic stroke. Results: Primary outcome was a composite of major extracranial bleeding and symptomatic intracranial hemorrhage within 30 days of anticoagulation initiation. Of 356 patients screened, 143 met inclusion criteria; 91 (64%) received early and 52 (36%) received late anticoagulation. Baseline demographics were similar between the cohorts. Primary 30-day outcome occurred in 12% (11/91) of the early and 10% (5/52) of the late cohort ( P = 0.78). No differences were observed in bleeding events, recurrent stroke, embolism, or mortality at 30 or 90 days. On multivariable analysis, P2Y12 inhibitor use was associated with increased risk of the primary outcome (OR 5.241, 95% CI 1.295-21.206, P = 0.02). Conclusions and Relevance: Early anticoagulation after ischemic stroke was not associated with higher bleeding risk and may reduce hospital stay, suggesting that early initiation may be safe. Larger prospective studies are needed to determine optimal timing of anticoagulation.
Introduction: Acute acetaminophen poisoning remains the leading cause of acute hepatic failure in the country. Fomepizole has been suggested to improve outcomes in case reports involving acetaminophen-poisoned patients. The purpose of this study is to evaluate if fomepizole impacts mortality and other clinical outcomes in acetaminophen-poisoned patients seen at the bedside by medical toxicology physicians. Methods: This was a secondary analysis of cases reported to the Toxicology Investigators Consortium (ToxIC) Core Registry between January 1, 2010, and October 28, 2024. Mono-substance, acetaminophen-poisoned patients managed with NAC therapy were identified. Patients were excluded if they were reported to have a chronic or parenteral acetaminophen exposure or did not receive NAC therapy. Patients were then stratified into two groups: NAC therapy alone (NAC), or NAC therapy in combination with fomepizole (NAC+4MP). The primary outcome of the study was in-hospital mortality. Other secondary clinical endpoints were also collected. Results: Cases of acute acetaminophen poisoning managed with NAC therapy (n = 3789) were identified and divided into two cohorts: the NAC cohort (n = 3665) and the NAC+4MP cohort (n = 124). Overall, mortality was higher with combination therapy compared with NAC monotherapy (OR 3.59, P = 0.01 [95% CI (1.23, 8.67)]). Metabolic acidosis, AST/ALT > 1000, coagulopathy, vitamin K use, vasopressor use, transfusion, and renal replacement therapy use were also more common in the combination group. Conclusion: In this large observational database study of acetaminophen poisoning, use of fomepizole and NAC therapy was not associated with improved mortality.
This study evaluated whether shorter time to achieving targeted guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) was associated with greater improvement in left ventricular ejection fraction (LVEF). GDMT reduces morbidity and mortality in HFrEF. It is unclear whether the speed of achieving target doses influences improvement in LVEF or related outcomes. This retrospective study included new HFrEF patients seen in a heart failure clinic between January 1 st , 2021 and January 1 st , 2023 that met study criteria. The primary outcome was improvement in LVEF. Secondary outcomes included reduction in mitral valve regurgitation (MVR) severity and differences in LVEF improvement by provider type. Titration velocity was defined as time from first heart failure visit to attainment of target or maximally tolerated GDMT doses. Eighty-seven patients were included in the study (mean age 61 years; 64.4% male; 58.6% white). After GDMT titration, 90.8% demonstrated improvement in LVEF. Mean time to full GDMT titration was 146.6 days (<6 months). Mean LVEF improvement was 19.5% (<3 months), 19.1% (3-6 months), 21.0% (6-9 months), and 17.3% (>9 months), with no significant difference among groups ( P = 0.823). No significant differences were observed in MVR reduction ( P = 0.523) or LVEF improvement by provider type ( P = 0.703). GDMT titration velocity was not associated with significant differences in LVEF improvement. These findings support individualized GDMT optimization rather than emphasizing rapid dose escalation and suggest potential benefits of longer therapy duration allowing additional time for specialty evaluation and avoiding premature device implantation.
BackgroundDexmedetomidine is commonly used in the intensive care unit (ICU) and is associated with hemodynamic adverse events, including hypotension and bradycardia. Use of dexmedetomidine has not been described in critically ill patients with right ventricular (RV) dysfunction and may be particularly relevant given the tenuous hemodynamics in this patient population.ObjectiveDetermine the prevalence of adverse events in adult ICU patients with RV dysfunction receiving dexmedetomidine.MethodsThis single-center, retrospective cohort study included adult ICU patients with RV dysfunction measured by echocardiogram who received dexmedetomidine between January 2017 and December 2022. The primary outcome was a composite of adverse events after dexmedetomidine initiation including bradycardia, hypotension, increasing vasopressor/inotrope requirements, and asystole. Secondary outcomes included individual components of the primary outcome and a comparison of adverse events based on RV dysfunction severity.ResultsA total of 245 patients met study inclusion criteria. A total of 178 adverse events occurred in 153 patients (62.4%). The most common adverse event was hypotension occurring in 129 patients (72.5%). Increased vasopressor requirements occurred in 35 patients (19.7%), and mean change in norepinephrine equivalents from baseline was 0.06 µg/kg/min. Adverse event rates did not differ among patients with mild, moderate, or severe RV dysfunction.ConclusionAdult ICU patients with RV dysfunction receiving dexmedetomidine experienced high rates of hypotension and increased vasopressor requirements. Findings from this study may assist in tailoring sedation regimens for critically ill patients with RV dysfunction. Future research is needed to explore optimal sedative agents in this patient population.
Concomitant therapy with anticoagulants and antiplatelets in patients with atrial fibrillation and chronic coronary syndrome significantly increases the risk of bleeding with no added reduction in cardiovascular disease risk over anticoagulation alone. The primary objective was to evaluate an evidence-based antiplatelet stewardship service designed to deprescribe single antiplatelet therapy in patients with atrial fibrillation receiving oral anticoagulants and a single antiplatelet therapy for both primary and secondary prevention of cardiovascular disease. This retrospective study included adult patients aged older than 18 years with atrial fibrillation who were seen at a tertiary academic heart failure center and received therapeutic oral anticoagulants and single antiplatelet therapy for any cardiovascular secondary or primary prevention. The primary outcome was the acceptance of the antiplatelet deprescribing intervention by both providers and patients. The secondary outcomes included provider- or patient-accepted antiplatelet deprescribing intervention. A total of 71 patients were included in the final cohort of this study. The most common indication for the antiplatelet therapy was chronic coronary disease at 69.0 % followed by primary prevention at 14.1% and stroke at 11.3%. The most common antiplatelet therapy was aspirin 81 mg once daily (83.1%), followed by clopidogrel 75 mg once daily(16.9%). Among the 71 patients, 54 (76.1%) were on non-guideline directed antiplatelet therapy. Of the 54 recommendations, 50 (92.6%) were accepted by the providers, and 43 of the 50 provider-accepted recommendations (86.0%) were accepted by the patients. Conclusion: A pharmacist-led antiplatelet deprescribing service is feasible in a tertiary heart failure cardiology outpatient setting. Most recommendations were accepted by the providers and patients.